Press releases
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
More ▼
Key statistics
On Friday, Atara Biotherapeutics Inc (0HIY:LSE) closed at 0.5502, 175.65% above the 52 week low of 0.1996 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.5502 |
Average volume | 6.85k |
---|---|
Shares outstanding | 120.42m |
Free float | 109.22m |
P/E (TTM) | -- |
Market cap | 67.54m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 20 minutes, as of May 31 2024 19:12 BST.
More ▼